<DOC>
	<DOCNO>NCT00949975</DOCNO>
	<brief_summary>The primary objective evaluate dose-response relationship efficacy AZD9668 3 dose level compare placebo symptomatic COPD patient assess effect lung function symptom COPD .</brief_summary>
	<brief_title>A Dose Range Finding Study Evaluate Efficacy Safety AZD9668 Administered Orally Three Dose Levels Patients With Chronic Obstructive Pulmonary Disease ( COPD ) Treatment With Tiotropium</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Diagnosis COPD symptom 1 year Smokers exsmokers Males postmenopausal females 40 80 year old Able use electronic device Past history current evidence clinically significant heart disease Current diagnosis asthma Patients require long term oxygen therapy Treatment antibiotic within 4 week study visit 1b</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Chronic</keyword>
	<keyword>Obstructive</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Lung</keyword>
	<keyword>Respiratory disease</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety tolerability</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>COPD</keyword>
</DOC>